Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,474 across all filing types
Latest filing 2019-11-04 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2019
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/10/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities issued, with no financial performance data, management discussion, or earnings information. This type of document is a regulatory filing reporting share capital movements and related confirmations to the stock exchange. It is not a full financial report, earnings release, or management report. Given the detailed share capital movement data and the nature of the filing, it fits best under 'Share Issue/Capital Change' (SHA). The document length is substantial and contains substantive data on share capital changes, not just an announcement or certification, so it is not RNS or RPA. Therefore, the classification is SHA with high confidence.
2019-11-04 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 October 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/10/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory compliance report specific to share capital movements, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-11-01 English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY DIRECTORS AND CONTROLLING SHAREHOLDERS
Director's Dealing Classification · 100% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding an increase in shareholding by directors and controlling shareholders. It details the purchase of shares by executive directors and controlling shareholders, including the number of shares purchased, the price, and the resulting shareholding percentage. There is no financial report, earnings data, or regulatory filing of a financial nature. The content focuses on insider share transactions by company directors and controlling shareholders. Therefore, this fits the category of Director's Dealing (DIRS). The document length is under 5,000 characters and is an announcement, not a full report, which aligns with DIRS rather than a full financial report or regulatory filing.
2019-10-17 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 September 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/9/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on changes in the company's share capital structure during a specific month. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is a regulatory filing reporting share capital movements, typical for compliance with exchange rules. It is not an announcement of a report, nor a full financial report, but a regulatory disclosure of share capital changes. Therefore, it fits best under Regulatory Filings (RNS).
2019-10-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2019
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/9/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities issued during the month, with confirmations about compliance with listing rules. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting share capital movements and related confirmations to the stock exchange, typical of a capital/financing update or regulatory filing. Given the detailed nature of share capital movements and the monthly frequency, it aligns best with Capital/Financing Update (CAP). It is not a simple announcement or report publication, as it contains substantive data on share capital changes.
2019-10-02 English
INTERIM REPORT 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report 2019' and contains detailed financial statements such as the Condensed Consolidated Statement of Profit or Loss, Statement of Financial Position, Statement of Changes in Equity, and Statement of Cash Flows for the six months ended 30 June 2019. It also includes notes on accounting policies and application of new standards, which are typical components of an interim or quarterly financial report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-09-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.